Emerging role of immunotherapy in urothelial carcinoma—advanced disease
M Zibelman, C Ramamurthy, ER Plimack - Urologic Oncology: Seminars …, 2016 - Elsevier
Systemic therapy for metastatic urothelial carcinoma has seen minimal progress and no new
approved therapies in the past 20 years. However, with the approval of the checkpoint …
approved therapies in the past 20 years. However, with the approval of the checkpoint …
[引用][C] Emerging role of immunotherapy in urothelial carcinoma—Advanced disease
M Zibelman, C Ramamurthy, ER Plimack - Urologic Oncology: Seminars …, 2016 - cir.nii.ac.jp
Emerging role of immunotherapy in urothelial carcinoma—Advanced disease | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Emerging role of immunotherapy in urothelial carcinoma—Advanced disease
M Zibelman, C Ramamurthy, ER Plimack - Urologic Oncology: Seminars …, 2016 - infona.pl
Systemic therapy for metastatic urothelial carcinoma has seen minimal progress and no new
approved therapies in the past 20 years. However, with the approval of the checkpoint …
approved therapies in the past 20 years. However, with the approval of the checkpoint …
Emerging role of immunotherapy in urothelial carcinoma-Advanced disease
M Zibelman, C Ramamurthy… - Urologic …, 2016 - pubmed.ncbi.nlm.nih.gov
Systemic therapy for metastatic urothelial carcinoma has seen minimal progress and no new
approved therapies in the past 20 years. However, with the approval of the checkpoint …
approved therapies in the past 20 years. However, with the approval of the checkpoint …
Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
M Zibelman, C Ramamurthy, ER Plimack - Urologic Oncology, 2016 - europepmc.org
Systemic therapy for metastatic urothelial carcinoma has seen minimal progress and no new
approved therapies in the past 20 years. However, with the approval of the checkpoint …
approved therapies in the past 20 years. However, with the approval of the checkpoint …